You have 9 free searches left this month | for more free features.

NK-cell

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Extranodal NK T Cell Lymphoma, NK-Cell Leukemia Trial in Xuzhou (Anti-CD56 CAR T)

Recruiting
  • Extranodal NK T Cell Lymphoma
  • NK-Cell Leukemia
  • Anti-CD56 CAR T
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Jul 10, 2023

AML, Adult, Minimal Residual Disease Trial in Tianjin (CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine)

Not yet recruiting
  • AML, Adult
  • Minimal Residual Disease
  • CD33/CLL1 dual CAR-NK cell
  • +5 more
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Aug 4, 2023

NK Cell, B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in Hubei (autologous NK cell)

Not yet recruiting
  • NK Cell
  • +2 more
  • autologous NK cell
  • Hubei, Xiangyang, China
    EC of Xiangyang No.1 People's Hospital Hubei University of Medic
Jun 19, 2023

Aggressive NK Cell Leukemia Trial in Hiroshima (PPMX-T003)

Recruiting
  • Aggressive NK Cell Leukemia
  • Hiroshima, Japan
    Hiroshima University Hospital
May 9, 2023

Leukemia Trial (Donor Enriched Activated Natural Killer Cell Infusion)

Withdrawn
  • Leukemia
  • Donor Enriched Activated Natural Killer Cell Infusion
  • (no location specified)
Dec 20, 2022

Colorectal Cancer Trial (anesthetic method)

Withdrawn
  • Colorectal Cancer
  • anesthetic method
  • (no location specified)
Jul 11, 2023

AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)

Recruiting
  • AML, Adult
  • CLL1 CAR-NK cell injection
  • Hangzhou, Zhejiang, China
    Clinical research ethics committee of the first affiliated hospi
Aug 30, 2023

Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

Recruiting
  • Immunotherapy
  • Multiple Myeloma
  • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 14, 2022

Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 2, 2023

T-Cell and NK-Cell Tumor Trial

Not yet recruiting
  • T-Cell and NK-Cell Neoplasm
    • (no location specified)
    Sep 28, 2023

    Acute Myeloid Leukemia in Children Trial in Saint Louis (CIML NK Cell Infusion, CD3+ T Cell Product Infusion)

    Recruiting
    • Acute Myeloid Leukemia in Children
    • CIML NK Cell Infusion
    • CD3+ T Cell Product Infusion
    • Saint Louis, Missouri
      Washington University School of Medicine
    Oct 26, 2022

    Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

    Recruiting
    • Peripheral T/NK Cell Lymphoma (R/R PTCL)
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 19, 2022

    Acute Myeloid Leukemia Trial in Saint Louis (Graft cell infusion, Tacrolimus, Mycophenolate mofetil)

    Recruiting
    • Acute Myeloid Leukemia
    • Graft cell infusion
    • +6 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jan 29, 2023

    Acute Myeloid Leukemia, MDS, Myeloproliferative Tumor Trial in Boston (CIML NK, Fludarabine, Cyclophosphamide)

    Recruiting
    • Acute Myeloid Leukemia
    • +3 more
    • CIML NK
    • +2 more
    • Boston, Massachusetts
    • +1 more
    Jan 6, 2023

    Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Boston (Interleukin-15

    Recruiting
    • Squamous Cell Carcinoma of the Head and Neck
    • Recurrent Head and Neck Squamous Cell Carcinoma
    • Interleukin-15 Superagonist (N-803)
    • +2 more
    • Boston, Massachusetts
      Dana Farber Cancer Institute
    Dec 2, 2022

    Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

    Recruiting
    • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
    • dualCAR-NK19/70 cell
    • Shanghai, Shanghai, China
      Shanghai Tongji Hospital, Tongji University School of Medicine
    Apr 24, 2023

    Lymphoma Trial in Houston (Radiation Therapy, Dexamethasone, Etoposide phosphate)

    Recruiting
    • Lymphoma
    • Radiation Therapy
    • +5 more
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Dec 9, 2022

    Ovarian Cancer Trial in Hangzhou (NKG2D CAR-NK)

    Recruiting
    • Ovarian Cancer
    • NKG2D CAR-NK
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Mar 26, 2023

    Colon Cancer Stage I Trial in Taoyuan (Magicell-NK contains NK cells suspended in 100 mL normal saline)

    Recruiting
    • Colon Cancer Stage I
    • Magicell-NK contains NK cells suspended in 100 mL normal saline
    • Taoyuan, Taiwan
      Chang Gung Memorial Hospital, Linkou
    Sep 28, 2022

    AML Trial in Hangzhou (NKG2D CAR-NK)

    Recruiting
    • AML
    • NKG2D CAR-NK
    • Hangzhou, Zhejiang, China
    • +1 more
    Feb 17, 2023

    Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed Trial in Tampa, Columbus (GEM/DOX + TGFBi expanded NK cells)

    Recruiting
    • Pediatric Sarcoma, Refractory
    • Pediatric Sarcoma, Relapsed
    • GEM/DOX + TGFBi expanded NK cells
    • Tampa, Florida
    • +1 more
    Jan 3, 2023

    PD-1 Antibody, DC-Cell, NK-Cell Trial (Pembrolizumab, Nivolumab, Sintilimab)

    Not yet recruiting
    • PD-1 Antibody
    • +3 more
    • (no location specified)
    Jul 14, 2022

    Biliary Tract Cancer Trial in Seoul ('SMT-NK' Inj (allogeneic Natural Killer cell), Pembrolizumab Injection [Keytruda])

    Completed
    • Biliary Tract Cancer
    • 'SMT-NK' Inj (allogeneic Natural Killer cell)
    • Pembrolizumab Injection [Keytruda]
    • Seoul, Korea, Republic of
    • +1 more
    Mar 28, 2022

    Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

    Recruiting
    • Myeloid Malignancies
    • Lymphoid Malignancies
    • NK Cell enriched-DLI only
    • NK-DLI + DUK-CPG-001
    • Durham, North Carolina
      Duke University Health System
    Mar 8, 2022

    Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor, Pediatric Supratentorial Tumor Trial in San Francisco (Universal Donor

    Not yet recruiting
    • Pediatric Brain Tumor
    • +2 more
    • Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells
    • Implantation
    • San Francisco, California
      University of California, San Francisco
    May 24, 2023